Improvement and exploration of potassium-competitive acid blockers dual therapy for the eradication of Helicobacter pylori
10.3969/j.issn.1006-5725.2024.19.024
- VernacularTitle:钾离子竞争性酸阻滞剂二联疗法根除幽门螺杆菌的改良与探索
- Author:
Weiwei CHEN
1
;
Ruolin PENG
;
Yi QU
;
Zhenyu ZHANG
Author Information
1. 南京医科大学附属南京医院(南京市第一医院)消化内科(江苏南京 210006)
- Keywords:
Helicobacter pylori;
potassium-competitive acid blockers;
amoxicillin;
dual therapy
- From:
The Journal of Practical Medicine
2024;40(19):2806-2812
- CountryChina
- Language:Chinese
-
Abstract:
Helicobacter pylori infection is an important causative factor in a variety of gastrointestinal diseases,such as atrophic gastritis,peptic ulcer disease,and gastric cancer.Timely eradication treatment is con-ducive to maintaining the health of patients.With the increase of drug resistance in Helicobacter pylori,dual therapy with proton pump inhibitors combined with high-dose amoxicillin has gradually gained attention.Potassium-competitive acid blockers are new types of antacids that have a faster onset of action and a longer lasting acid sup-pression effect than traditional proton pump inhibitors,making it more suitable for dual therapy.In recent years,scholars have carried out a lot of exploration,improvement and verification of potassium-competitive acid blockers dual therapy,and this article reviews its research progress.
